Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–801.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;7(16):4448–61.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and Blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24–34.
Cabannes-Hamy A, Brissot E, Leguay T, Huguet F, Chevallier P, Hunault M, et al. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. Haematologica. 2022;107(9):2072–80.
Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK, et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137(4):471–84.
Laqua A, Raifer H, Kelm M, Horns J, Sharma A, Möricke A, et al. In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 study. Blood. 2023;142(Supplement 1):595.
Goekbuget N, Schwartz S, Faul C, Topp MS, Subklewe M, Renzelmann A, et al. Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph/BCR::ABL negative B-Precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. Blood. 2023;142(Supplement 1):964.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of Blinatumomab vs Chemotherapy on event-free survival among children with high-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: a Randomized Clinical Trial. JAMA. 2021;325(9):843–54.
O’Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–101.
Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556–64.
Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022;9(12):e878–85.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836–47.
Add Comment